Histopatología y bioquímica sanguínea en ovinos tratados con un fasciolicida intramuscular experimental
Article Sidebar
Main Article Content
Abstract
El objetivo de este trabajo fue determinar si la administración del profármaco fasciolicida fosfatriclaben inyectable, en dosis única a 6 mg/kg por vía intramuscular en ovinos criollos, produce reacciones adversas reflejadas en los perfiles histopatológicos, particularmente en los tejidos involucrados en el metabolismo de los fármacos, y bioquímico sanguíneo. Para este efecto, se formaron dos grupos de ovinos. El grupo 1 (G1) de 15 ovinos recibió tratamiento; el grupo 2 (G2) de 5 ovinos fungió como control. Los días 0, 7, 14, 28 y 35 post-tratamiento, se tomaron muestras de hígado, riñón y sitio de inyección para histopatología; así como muestras sanguíneas para su estudio bioquímico. Los resultados no mostraron alteraciones histopatológicas de importancia, ni diferencias significativas en la bioquímica sanguínea (P < 0.05); los valores de los analitos se mantuvieron dentro del rango de referencia. Se estima que el profármaco de prueba podría presentar características de seguridad, similares a las de su precursor, el triclabendazol.
Article Details
References
Taylor M, Coop R, Wall R. Veterinary Parasitology. 4th ed. West Sussex, UK: Wiley-Blackwell; 2016. pp. 84–90, 201–210. doi: 10.1002/9781119073680.
Elliott TP, Kelley JM, Rawlin G, Spithill TW. High prevalence of fasciolosis and evaluation of drug efficacy against Fasciola hepatica in dairy cattle in the Maffra and Bairnsdale districts of Gippsland, Victoria, Australia. Veterinary Parasitology. 2015; 209(1-2): 117–124. doi: 10.1016/j.vetpar.2015.02.014.
Mehmood K, ZhangH, Sabir AJ, Abbas RZ, Ijaz M, Durrani AZ, et. al. A review on epidemiology, global prevalence and economical losses of fasciolosis in ruminants. Microbial Pathogenesis. 2017; 109:253–262. doi: 10.1016/j.micpath.2017.06.006.
World Health Organization. Food borne trematode infection-fascioliasis. 2024. https://www.who.int/foodborne_trematode_infections/fascioliasis/en/
Centres for Disease Control and Prevention. Fasciola Biology. 2024. https://www.cdc.gov/parasites/fasciola/biology.html
Ashrafi K, Mas-Coma S. Fasciola gigantica transmission in the zoonotic fascioliasis endemic lowlands of Guilan, Iran: Experimental assessment. Veterinary Parasitology. 2014; 205(1–2):96–106. doi: 10.1016/j.vetpar.2014.07.017.
Savioli L, Chitsulo L, Montresor A. New opportunities for the control of fascioliasis. Bulletin of the World Health Organization. 1999;77(4):300. PMCID: PMC2557651.
Dalton JP, editor. Fasciolosis. 2a ed. Dublin, Irlanda: CABI Publishing Series; 2021. 519 pp.
Boray JC, Crowfoot PD, Strong MB, Allison JR, Schellenbaum M, von Orelli M, et al. Treatment of immature and mature Fasciola hepatica infections in sheep with triclabendazole. Veterinary Record. 1983;113(14):315–317. doi: 10.1136/vr.113.14.315.
Lindenberg M, Kopp S, Dressman JB. Classification of orally administered drugs on the World Health Organization Model list of Essential Medicines according to the biopharmaceutics classification system. European Journal of Pharmaceutics and Biopharmaceutic. 2004;58(2):265–278. doi: 10.1016/j.ejpb.2004.03.001.
Flores M, Ibarra F, Jung H, Hernández A, Vera Y, Castillo R. Novel triclabendazole prodrug: a highly water soluble alternative for the treatment of fasciolosis. Bioorganic & Medicinal Chemistry Letters. 2017;27(3):616–619. doi: 10.1016/j.bmcl.2016.12.004.
Arias GR, Vera MY, Flores RM, Castillo R, Hernández CA, Ibarra VF. Efficiency comparison of experimental fosfatriclaben with three commercial fasciolicides in experimentally infected sheep. Parasitology Research. 2020;119(8):2687–2693. doi: 10.1007/s00436-020-06705-4.
Flores RM, Leyva GG, Rojas CT, Cruz MI, Hernández CA, Vera MY, et. al. Fosfatriclaben, a prodrug of triclabendazole: Preparation, stability, and fasciolicidal activity of three new intramuscular formulations. Veterinary Parasitology. 2024; 327:110113. doi: 10.1016/j.vetpar.2024.110113.
Holloway K, Green T. Comités de farmacoterapia. Guía Práctica. Ginebra, Suiza: Organización Mundial de la Salud. 2003. 155 pp. https://iris.who.int/bitstream/handle/10665/69224/WHO_EDM_PAR_2004.1_spa.pdf?sequence=1
Brumbaugh GW. Adverse drug reactions and interactions in the horse. Veterinary Clinics of North America: Equine Practice. 2001;17(3):445–453. doi: 10.1016/S0749-0739(17)30044-5.
Maddison JE. Adverse drug reactions: Report of the Australian Veterinary Association Adverse Drug Reaction Subcommittee, 1994. Australian Veterinary Journal. 1996;73(4):132–136. doi: 10.1111/j.1751-0813.1996.tb10005.x.
Consolini AE, Ragone MI. Farmacodinamia general e interacciones medicamentosas. La Plata, Argentina: Ed. de la Universidad Nacional de La Plata EDULP. 2017.214 p. doi: 10.35537/10915/67056.
Sánchez-González MJ, Barbarroja-Escudero J, Antolín-Amérigo D, Rodríguez-Rodríguez M. Reacciones alérgicas a fármacos. Madrid, España: Medicine-Programa de Formación Médica Continuada Acreditado. 2013;11(29):1808–1818. doi: 10.1016/S0304-5412(13)70531-6.
Garbi MR, Pastor E, Garbi A, Guilhem D, Cañete R. Reacciones adversas en ensayos clínicos con nuevos fármacos conducidos en Brasil. Años 2000 y 2012. Revista Médica Electrónica. 2015;37(1):18–29.
Lynch SS. Eficacia y seguridad del fármaco. Mamual MSD, Merck & Co, Inc., Rahway, New Jersey; 2022. p. 4. https://www.msdmanuals.com/es-mx/professional/farmacología-clínica/conceptos-farmacoterapéuticos/eficacia-y-seguridad-del-fármaco
Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. The Lancet. 2000;356(9237):1255–1259. doi: 10.1016/S0140-6736(00)02799-9.
Laurence DR, Carpenter JR. A Dictionary of Pharmacology and Allied Topics. 2nd ed. Ámsterdam, Netherlands: Elsevier; 1998. pp. 8–9.
Smith Marsh DE. Reacciones adversas a los fármacos. MANUAL MSD, Merck & Co, Inc., Rahway, New Jersey 2023. p. 5. https://www.msdmanuals.com/es-mx/professional/farmacología-clínica/reacciones-adversas-a-los-fármacos/reacciones-adversas-a-los-fármacos
Rieder MJ. Mechanisms of unpredictable adverse drug reactions. Drug Safety. 1994;11(3):196–212. doi: 10.2165/00002018-199411030-00005.
Davis LE, Scalley RD, Abbitt LE, Forney SD. Pharmacologic basis of adverse drug reactions. The Bovine Practitioner. 1977;(12):2–9. doi: 10.21423/bovine-vol1977no12p2-9.
Gobierno de México. Conceptos básicos de toxicología [PDF]. El Portal Único del Gobierno; 2024. p. 4. https://www.gob.mx/cms/uploads/attachment/file/26572/conceptos.pdf
Uppal RP. Adverse drug reactions and interactions in veterinary practice. Intas Polivet. 2000;1(1):13–22. https://www.cabidigitallibrary.org/doi/pdf/10.5555/20053130986
Montané E, Santesmases J. Reacciones adversas a medicamentos. Medicina Clínica. 2020; 154(5):178–184. doi: 10.1016/j.medcli.2019.08.007.
Arunvikram K, Mohanty I, Sardar KK, Palai S, Sahoo G, Patra RC. Adverse drug reaction and toxicity caused by commonly used antimicrobials in canine practice. Veterinary World. 2014;7(5):299–305. doi: 10.14202/vetworld.2014.299–305.
Servicio Nacional de Sanidad, Inocuidad y Calidad Agroalimentaria. Criterios de funcionamiento de métodos analíticos. 2016. p. 31. https://www.gob.mx/senasica/documentos/criterios-para-el-funcionamiento-aplicacion-e-interpretacion-de-metodos-analiticos?state=published
Servicio Nacional de Sanidad, Inocuidad y Calidad Agroalimentaria. Programa nacional de control y monitoreo de residuos tóxicos en bienes de origen animal, recursos acuícolas y pesqueros 2017 y resultados del 2016 [PDF]. 2017. p. 22. https://www.gob.mx/cms/uploads/attachment/file/265356/Programa_Nacional_de_Control_y_Monitoreo_de_Residuos_T_xicos_2017.pdf
Arrieta D, Comerma Steffensen S, Zerpa H. Adverse drug interactions in bovine. En: Salomon J, Romero R, Arias M, Diaz H, editors. XXIX Workshop on Beef Cattle. Maracay, Venezuela: Universidad Central de Venezuela; 2015. pp. 1–20. https://www.researchgate.net/publication/330508091_ADVERSE_DRUG_INTERACTIONS_IN_BOVINE
Cano A, Cifuentes LM, Amariles PJ. Toxicidad hepática causada por medicamentos: revisión estructurada. Revista Colombiana de Gastroenterología. 2017;32(4):337–348. doi: 10.22516/25007440.177.
Calderón C, Guzmán G, Sarmiento J, Gómez D, Joya A, Ríos L, et al. Nefrotoxicidad inducida por medicamentos. Médicas UIS. 2011;24(1):65–85. https://revistas.uis.edu.co/index.php/revistamedicasuis/article/view/2583/2905
Davis JL. Recognizing and treating adverse drug reactions (Proceedings). NJ, USA: dvm 360; 2011. pp. 1–12. https://www.dvm360.com/view/recognizing-and-treating-adverse-drug-reactions-proceedings-0
Martín-Jiménez T. Farmacocinética I: absorción y distribución/metabolismo, excreción y modelos farmacocinéticos. En: LM Botana, T Martín-Jiménez, MF Landoni, editores. Farmacología y Terapéutica Veterinaria. Madrid, España: McGraw-Hill; 2002. pp. 3–4, 33.
Castell JV. El metabolismo de fármacos, generación de metabolitos reactivos y su papel en el origen de las reacciones inmunológicas a fármacos. Valencia, España: Universidad de Valencia. 2018;95–123. http://www.uv.es/jcastell/Metabolismo_de_farmacos.pdf
Patel M, Taskar KS, Zamek-Gliszczynski MJ. Importance of hepatic transporters in clinical disposition of drugs and their metabolites. The Journal of Clinical Pharmacology. 2016;56(S7);S23–39. doi: 10.1002/jcph.671.
Anadón Navarro A. Interacciones medicamentosas adversas en medicina veterinaria. En: Guía de Productos Zoosanitarios. 5a. ed. Madrid, España: Veterindustria. 1994. pp. 1247–1279.
Liu L, Liu X. Contributions of drug transporters to blood-brain barriers. En: X Liu y G Pan, editores. Drug transporters in drug disposition, effects and toxicity. Advances in Experimental Medicine and Biology. 2019;1141:407–466 p. doi: 10.1007/978-981-13-7647-4_9.
Paul JW. Clinical considerations regarding drug interactions in the bovine patient. The Bovine Practitioner. 1977;(12):9–14. doi: 10.21423/bovine-vol1977no12p9-14.
Servicio Nacional de Sanidad, Inocuidad y Calidad Agroalimentaria. Manual de Procedimientos para el Sacrificio Humanitario y la Disposición Sanitaria en Emergencias Zoosanitarias. 2011. 37 pp. https://www.gob.mx/cms/uploads/attachment/file/483431/Manual_de_procedimientos_para_el_sacrificio_humanitario_y_la_disposici_n....pdf
Comité de las Américas de Medicamentos Veterinarios. XX Seminario sobre Armonización del Registro y Control de Medicamentos Veterinarios. Ottawa, Canadá: CAMEVET-OIE; 2014. 66 p.
Palma C, Godoy C, Arboix M, Pérez R. Determinación de residuos de abamectina-triclabendazol en tejidos bovinos. Archivos de Medicina Veterinaria. 2006;38(3):265–271.doi: 10.4067/s0301-732x2006000300011.
Russell WMS, Burch RL. The Sources, Incidence, and Removal of Inhumanity. En. The Principles of Humane Experimental Technique. Wheathampstead, UK: The Universities Federation for Animal Welfare. 1992; pp. 64–146.
Scientific Committees G. Three Rs Principle (in Animal Experimentation). Comisión Europea. 2024. https://ec.europa.eu/health/opinions/es/primates-no-humanos/glosario/pqrs/principio-tres-erres.htm
Kramer M, Font E. Reducing sample size in experiments with animals: historical controls and related strategies. Biological Reviews. 2017;92(1):431–445. doi: 10.1111/brv.12237.
Centro Nacional de Servicios de Diagnóstico en Salud. Catálogo de Servicios [PDF]. 2022. https://www.gob.mx/cms/uploads/attachment/file/706971/C001-8_Cat_logo_de_Servicios_.pdf
Sutherland JJ, Yonchev D, Fekete A, Urban L. A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs. Nature Communications. 2023;14:4323. doi: 10.1038/s41467-023-40064-9.
Brown SA, Garry FB. Comparison of serum and renal gentamicin concentrations with fractional urinary excretion tests as indicators of nephrotoxicity. Journal of Veterinary Pharmacology and Therapeutics. 1988;11(4):330–337. doi: 10.1111/j.1365-2885.1988.tb00192.x.
Hsu H W, Ahrens FA. Drug interactions and adverse drug reactions. En: HW Hsu, editor. Handbook of Veterinary Pharmacology. Iowa, US: Wiley-Blackwell; 2008. pp. 461–470.
McDuffie JE, Gao J, Ma J, la D, Bittner A, Sonee M, et al. Novel genomic biomarkers for acute gentamicin nephrotoxicity in dog. Open Journal of Molecular and Integrative Physiology. 2013;3(3):125–133. doi: 10.4236/ojmip.2013.33018.
Velasco A, Velasco M. Reacciones adversas medicamentosas (RAM). Anales de la Real Academia de Medicina y Cirugía de Valladolid. 2018;55:243–267. https://dialnet.unirioja.es/servlet/articulo?codigo=7141899
Miller WH, Griffin CE, Campbell KL. Bacterial skin diseases. En: WH Miller, CE Griffin, KL Campbell, editors. Muller and Kirk’s small animal dermatology. 7th ed. St. Louis, Missouri, US: Elsevier; 2012. pp. 191–192.
Voie KL, Lucas BE, Schaeffer D, Kim D, Campbell KL, Lavergne SN. The effect of ‘allergenic’ and ‘nonallergenic’ antibiotics on dog keratinocyte viability in vitro. Veterinary Dermatology. 2013;24(5):501-e119. doi: 10.1111/vde.12060.
Mancilla MG, Torres JFJ, Ayala Burgos AJ. Dosis, excesos y reacciones adversas del closantel en ovinos y caprinos en México. Bioagrociencias. 2022;15(1):39–46. doi: 10.56369/BAC.4255.
Villegas F, Angles R, Barrientos R, Barrios G, Valero MA, Hamed K, et. al. Administration of triclabendazole is safe and effective in controlling fascioliasis in an endemic community of the Bolivian altiplano. PLOS Neglected Tropical Diseases. 2012;6(8):e1720. doi: 10.1371/journal.pntd.0001720.
Lecaillon JB, Godbillon J, Campestrini J, Naquira C, Miranda L, Pacheco R, et. al. Effect of food on the bioavailability of triclabendazole in patients with fascioliasis. British Journal of Clinical Pharmacology. 1998;45(6):601–604. doi: 10.1046/j.1365-2125.1998.00725.x.
El-Karaksy H, Hassanein B, Okasha S, Behairy B, Gadallah I. Human fascioliasis in Egyptian children: successful treatment with triclabendazole. Journal of Tropical Pediatrics. 1999;45(3):135–138. doi: 10.1093/tropej/45.3.135.
Apt W, Aguilera X, Vega F, Miranda C, Zulantay I, Perez C, et al. Treatment of human chronic fascioliasis with triclabendazole: drug efficacy and serologic response. American Journal of Tropical Medicine and Hygiene. 1995;52(6):532–535. doi: 10.4269/ajtmh.1995.52.532.
McCarthy JS, Moore TA. Drugs for helminths. En: JE Bennett , R Dolin R, MJ Blaser, editores. Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases. 8th ed. Vol. 1. Amsterdam, The Netherlands: Elsevier; 2015. pp. 519–527. doi: 10.1016/B978-1-4557-4801-3.00042-4.
Wolff K, Eckert J, Schneiter G, Lutz H. Efficacy of triclabendazole against Fasciola hepatica in sheep and goats. Veterinary Parasitology. 1983;13(2):145–150. doi: 10.1016/0304-4017(83)90074-2.
License
Veterinaria México OA by Facultad de Medicina Veterinaria y Zootecnia - Universidad Nacional Autónoma de México is licensed under a Creative Commons Attribution 4.0 International Licence.
Based on a work at http://www.revistas.unam.mx
- All articles in Veterinaria México OA re published under the Creative Commons Attribution 4.0 Unported (CC-BY 4.0). With this license, authors retain copyright but allow any user to share, copy, distribute, transmit, adapt and make commercial use of the work, without needing to provide additional permission as long as appropriate attribution is made to the original author or source.
- By using this license, all Veterinaria México OAarticles meet or exceed all funder and institutional requirements for being considered Open Access.
- Authors cannot use copyrighted material within their article unless that material has also been made available under a similarly liberal license.